These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 35926811)

  • 1. CDX2 expression in primary skin tumors-case series and review of the literature.
    Tekin B; Kundert P; Yang HH; Guo R
    Hum Pathol; 2022 Nov; 129():1-10. PubMed ID: 35926811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDX2 expression in cutaneous metastatic carcinomas and extramammary Paget's Disease.
    Lora V; Kanitakis J
    Anticancer Res; 2009 Dec; 29(12):5033-7. PubMed ID: 20044613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDX2 and LEF-1 expression in pilomatrical tumors and their utility in the diagnosis of pilomatrical carcinoma.
    Tumminello K; Hosler GA
    J Cutan Pathol; 2018 May; 45(5):318-324. PubMed ID: 29369390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDX2 and SATB2 positivity in pilomatrix carcinoma: Avoiding an erroneous diagnosis of cutaneous metastasis of gastrointestinal origin.
    Kenny B; Osmond A
    J Cutan Pathol; 2022 Apr; 49(4):399-402. PubMed ID: 34797586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of CDX2 and Thyroid Transcription Factor-1 in Oropharyngeal Undifferentiated Carcinomas: A Potential Diagnostic Pitfall.
    Chernock RD; Bibbey S; El-Mofty SK; Carpenter DH; Lewis JS
    Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):268-273. PubMed ID: 27389559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites.
    De Lott LB; Morrison C; Suster S; Cohn DE; Frankel WL
    Arch Pathol Lab Med; 2005 Sep; 129(9):1100-5. PubMed ID: 16119980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
    McCluggage WG; Shah R; Connolly LE; McBride HA
    Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Case of Biphenotypic Adnexal Carcinoma With Bowenoid and Basaloid Features: Focus on the Expression of SOX9 and Wnt Signaling Pathway Molecules, Including CDX2.
    Sugimoto A; Fujimoto M; Masuo Y; Nakagawa Y; Yamada Y; Kono F; Haga H
    Am J Dermatopathol; 2023 Dec; 45(12):835-838. PubMed ID: 37883950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDX2 may be a useful marker to distinguish primary ovarian carcinoid from gastrointestinal metastatic carcinoids to the ovary.
    Desouki MM; Lioyd J; Xu H; Cao D; Barner R; Zhao C
    Hum Pathol; 2013 Nov; 44(11):2536-41. PubMed ID: 24029704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
    Winn B; Tavares R; Matoso A; Noble L; Fanion J; Waldman SA; Resnick MB
    Hum Pathol; 2010 Jan; 41(1):123-8. PubMed ID: 19800103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
    Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
    Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demonstration of CDX2 is highly antibody dependant.
    Borrisholt M; Nielsen S; Vyberg M
    Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):64-72. PubMed ID: 22595949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunophenotypic differences between intestinal-type and low-grade papillary sinonasal adenocarcinomas: an immunohistochemical study of 22 cases utilizing CDX2 and MUC2.
    Cathro HP; Mills SE
    Am J Surg Pathol; 2004 Aug; 28(8):1026-32. PubMed ID: 15252308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody.
    Bayrak R; Haltas H; Yenidunya S
    Diagn Pathol; 2012 Jan; 7():9. PubMed ID: 22268990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation.
    Winn B; Tavares R; Fanion J; Noble L; Gao J; Sabo E; Resnick MB
    Hum Pathol; 2009 Mar; 40(3):398-404. PubMed ID: 18992917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDX-2 expression in malignant germ cell tumors of the testes, intratubular germ cell neoplasia, and normal seminiferous tubules.
    Lee MJ; Vogt AP; Hsiao W; Osunkoya AO
    Tumour Biol; 2012 Dec; 33(6):2185-8. PubMed ID: 22895825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression.
    Landau MS; Kuan SF; Chiosea S; Pai RK
    Hum Pathol; 2014 Aug; 45(8):1704-12. PubMed ID: 24908142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas.
    Werling RW; Yaziji H; Bacchi CE; Gown AM
    Am J Surg Pathol; 2003 Mar; 27(3):303-10. PubMed ID: 12604886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin.
    Jaffee IM; Rahmani M; Singhal MG; Younes M
    Arch Pathol Lab Med; 2006 Oct; 130(10):1522-6. PubMed ID: 17090195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
    Groisman GM; Meir A; Sabo E
    Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.